{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-23-017571","form_type":"8-K","ticker":"BNBX","cik":"0000744452","company_name":"BNB PLUS CORP.","filed_at":"2023-02-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:47.964041+00:00","generated_at":"2026-06-19T21:09:07.707749+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Applied DNA Q1 revenues $5.3M (+26% YoY); operating loss narrows to $1.2M","bullets":["Total revenues $5.3M vs $4.2M in prior-year period; clinical lab service rev $4.5M (+41% YoY).","Gross profit $2.4M (45% margin) vs $1.1M (27%), driven by higher testing volumes and cost management.","Operating loss $1.2M vs $4.7M loss a year ago; Adjusted EBITDA -$1.1M vs -$2.7M.","Cash $12.9M at Dec 31, 2022; 7.3M warrants outstanding with potential proceeds of ~$26.6M.","cGMP facility build-out initiated within HQ; PGx validation package to be filed with NYSDOH."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-23-017571","json":"https://secwatch.observer/filing/0001104659-23-017571.json","markdown":"https://secwatch.observer/filing/0001104659-23-017571.md","text":"https://secwatch.observer/filing/0001104659-23-017571.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/744452/000110465923017571/0001104659-23-017571-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/744452/000110465923017571/tm236000d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-19T21:09:07.707749+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"9ec16ffd4ffafdb629c28738d5ee2a8d1f26a1b4","claim":"BNB PLUS CORP. reported first quarter of fiscal 2023, ended December 31, 2022 results: revenue $5.3 million.","evidence_excerpt":"Applied DNA Reports First Quarter Fiscal 2023 Financial Results - Total Revenues of $5.3 Million","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/744452/000110465923017571/0001104659-23-017571-index.htm","confidence":0.4,"family_label":"Earnings Releases","details":[{"label":"Period","value":"first quarter of fiscal 2023, ended December 31, 2022"},{"label":"Revenue","value":"$5.3 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}